SEATTLE, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Athira. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Athira, are expected to be $204.0 million. Athira’s common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “ATHA” on September 18, 2020. The offering is expected to close on September 22, 2020, subject to satisfaction of customary closing conditions. In addition, Athira has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of Athira’s common stock at the initial public offering price less the underwriting discounts and commissions.
Read more:
Athira Pharma Announces Pricing of Initial Public Offering
